Asahi Kasei Pharma obtains approval for Doptelet® Tablet 20 mg for the additional indication of persistent and chronic immune thrombocytopenia
August 25, 2025
Asahi Kasei Pharma Corp.
Asahi Kasei Pharma announces that Doptelet® Tablet 20 mg (generic name: avatrombopag maleate), for which it obtained exclusive distribution rights in Japan from Swedish Orphan Biovitrum Japan Co., Ltd. (Sobi Japan), has been approved for the additional indication of persistent and chronic immune thrombocytopenia (ITP).
Avatrombopag, a thrombopoietin receptor agonist which stimulates the production of platelets, was approved in Japan in March 2023 for the indication of improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure1. Sold in Japan by Asahi Kasei Pharma, avatrombopag has been approved for the treatment of chronic ITP2 in the U.S., Europe, and other markets.
By providing a new therapeutic option for persistent and chronic ITP, Asahi Kasei Pharma aims to realize a society where “no one should have to give up doing what they love due to illness” in accordance with its mission “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science.”
Product overview of Doptelet® Tablet 20 mg (additional indication underlined)
- Product name
- Doptelet® Tablet 20 mg
- Generic name
- Avatrombopag maleate
- Indication
- Improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure
- Persistent and chronic immune thrombocytopenia (ITP)
- Dosage and administration
- For improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure
For adults, ordinarily administer the following dosage of avatrombopag orally once per day after a meal for 5 days.
If platelet count prior to administration is at least 40,000/µL but less than 50,000/µL: 40 mg
If platelet count prior to administration is less than 40,000/µL: 60 mg
For persistent and chronic immune thrombocytopenia (ITP)
For adults, ordinarily administer 20 mg of avatrombopag orally once per day after a meal as initial dose. Subsequently, the dosage and administration method should be adjusted according to the platelet count and symptoms. The maximum dose should be 40 mg once per day. - Manufacture
- Swedish Orphan Biovitrum Japan Co., Ltd.
- Sale
- Asahi Kasei Pharma Corporation
- Approval
- August 25, 2025
Doptelet® Tablet 20 mg
About Swedish Orphan Biovitrum AB
Founded in 2009, Sobi is a specialized international biopharmaceutical company headquartered in Stockholm, Sweden, transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia. To learn more, visit https://www.sobi.com/
- 1Invasive procedures such as upper gastrointestinal endoscopy, transarterial chemoembolization (TACE) for hepatocellular carcinoma, radiofrequency ablation, etc.
- 2The official indication in Europe is “primary chronic immune thrombocytopenia.”